RT Journal Article
SR Electronic
T1 730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A825
OP A825
DO 10.1136/jitc-2023-SITC2023.0730
VO 11
IS Suppl 1
A1 Li, Daneng
A1 Spira, Alexander I
A1 Mamdani, Hirva
A1 Leddon, Jennifer
A1 Fong, Yuman
A1 Chong, Leslie
A1 Fein, Seymour
A1 Ede, Nick
A1 McCurry, Ursula
A1 Seiz, Amanda
A1 Polasek, Melissa
A1 Yavrom, Sharon
A1 Selvaggi, Giovanni
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A825.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.